Lung Cancer
Adjuvant Pembrolizumab Gets FDA Approval in NSCLC
January 26, 2023
Article
Pembrolizumab has been approved by the FDA as an adjuvant treatment for patients with stage IB, II, or IIIA following resection and platinum-based chemotherapy.
Children Exposed to Maternal Cancer Show Normal Cognitive and Behavioral Outcomes
January 24, 2023
Article
An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.
A Look Back at 2022 FDA Approvals in Oncology
January 02, 2023
Podcast
In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.
Frontline Durvalumab Does Not Elicit Significant OS Improvement in Advanced, PD-L1-High NSCLC
December 29, 2022
Article
In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.
Upfront Dostarlimab/Chemotherapy Yields Better Risk Reduction Than Pembrolizumab/Chemotherapy in NSCLC
December 14, 2022
Article
Patients with metastatic non-squamous non–small cell lung cancer who received frontline dostarlimab (Jemperli) plus chemotherapy experienced a risk of disease progression or death that was 30% greater than that experienced with pembrolizumab (Keytruda).
Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLC
December 13, 2022
Article
Adagrasib has received accelerated approval for KRAS G12C mutated non–small cell lung cancer. The prescribing label comes with warnings for gastrointestinal toxicities, QTC interval prolongation, hepatotoxicity, and interstitial lung disease.
Private Medicare Plans Lead to Worse Oncologic Surgery Outcomes vs Traditional Medicare
November 30, 2022
Article
Private Medicare beneficiaries face high access barriers and increased mortality rates following oncologic resection than patients with traditional Medicare plans.
First-Line Tremelimumab/Durvalumab/Chemotherapy May Become New Standard of Care in EGFR/ALK Wild-Type NSCLC
November 22, 2022
Article
The combination of tremelimumab plus durvalumab plus chemotherapy, which was recently approved for patients with non–small cell lung cancer, could represent a new standard of care.
Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung Cancer
November 19, 2022
Article
As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.
Toripalimab Confers Survival Benefit to Treatment Naïve Patients With NSCLC
November 17, 2022
Article
Patients with non–small cell lung cancer who received toripalimab experienced significant improvements in progression-free survival and overall survival.